The HESI Immuno-Safety Technical Committee’s humanized mouse project hosted Kristina Howard (FDA), who presented key findings from her SOT 2024 poster entitled “Donor specific toxicity of copanlisib identified using immune-humanized mice”. Copanlisib, an FDA-approved drug for lymphoma and breast cancer therapies, is being studied for its potential combined use with checkpoint inhibitors in immune-humanized mice. Initial studies revealed minimal toxicity in most cases, but significant immune responses in one donor highlight individual variations in drug effects.
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-3859
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.